替格瑞洛对急性冠状动脉综合征患者血小板聚集的影响被引量：7

Effects of ticagrelor on platelet aggregation in patients with acute coronary syndrome

导出

摘要目的比较替格瑞洛和氯吡格雷对急性冠状动脉综合征(ACS)患者血小板聚集的影响。方法 81例ACS患者被随机分为替格瑞洛组(A组,41例)和氯吡格雷组(B组,40例),比较两组服药前和服药后1、2、4、8、24h及治疗第7天的血小板最大聚集率(PMAR)、血小板聚集抑制率(IPA)及出血事件。结果两组服药前PMAR水平相近(P>0.05)。A组患者服药期间的PMAR均低于B组(P<0.01),IPA及IPA≥50%的患者比例均高于B组(P<0.01)。B组服药后2h的IPA低于服药后8h(P<0.01),而A组两个时间段IPA差异无统计学意义(P>0.05)。两组均只有轻微出血事件。结论在ACS患者,替格瑞洛较氯吡格雷更能有效地抑制血小板聚集;两药短期的安全性相仿。 Objective To compare the effects of ticagrelor and clopidogrel on platelet aggregation in the patients with acute coronary syndrome（ACS）.Methods A total of 81 patients with ACS was randomized into two groups of ticagrelor（group A,41cases）and clopidogrel（group B,40cases）.Maximum platelet aggregation rate（PMAR）,inhibition of platelet aggregation（IPA）and bleeding events were compared between two groups before,at 1,2,4,8,24 hours after administration and on the 7th day during treatment.Results PMAR of two groups was similar before medication（P〉0.05）,which was lower in group A than that in group B during treatment（P〈0.01）.IPA and IPA≥50%in group A were higher than those in group B（P〈0.01）.IPA at 2hours after medication was lower than that at 8hours in group B（P〈0.01）,which was similar in group A（P〉0.05）.Slight bleeding events were observed in two groups.Conclusion In the patients with ACS,ticagrelor is more effective in inhibiting the platelet aggregation than clopidogrel with similar safety in short-term.

作者钱晓东钱云霞杨向军程绪杰赵欣许海峰贺永明周亚峰

机构地区苏州大学附属第一医院心血管病科

出处《江苏医药》 CAS 2015年第1期30-32,共3页 Jiangsu Medical Journal

基金江苏省医学创新团队与领军人才项目(LJ201140) 江苏省"科教兴卫"医学重点人才项目(RC2011111)

关键词急性冠状动脉综合症血小板聚集替格瑞洛氯吡格雷 Acute coronary syndrome Platelet aggregation Ticagrelor Clopidogrel

分类号 R541 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献7

1Jneid H.The 2012 ACCF/AHA Focused Update of the Unstable Angina/Non-ST-Elevation Myocardial Infarction(UA/NSTEMI)Guideline:a critical appraisal[J].Methodist Debakey Cardiovasc J,2012,8(3):26-30.
2Kim HS,Cho DY,Park BM,et al.The effect of CYP2C19genotype on the time course of platelet aggregation inhibition after clopidogrel administration[J].J Clin Pharmacol,2014,54(8):850-857.
3Bonello L,Tantry US,Marcucci R,et al.Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate[J].J Am Coll Cardiol,2010,56(12):919-933.
4朱甜甜,李春坚,张秋,孔德玉,刘洁,陈波,贾恩志,陈磊磊,贾庆哲,陶正贤,张定国,戴振华,杨志健,曹克将,黄峻.氯吡格雷低反应性与支架内血栓形成的关系[J].江苏医药,2012,38(12):1401-1403. 被引量：6
5Gurbel PA,Bliden KP,Butler K,et al.Randomized doubleblind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease:the ONSET/OFFSET study[J].Circulation,2009,120(25):2577-2585.
6Wallentin L,Becker RC,Budaj A,et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes[J].N Engl J Med,2009,361(11):1045-1057.
7Stegnar M.Platelet function tests and resistance to antiplatelet therapy[J].Srp Arh Celok Lek,2010,138(Suppl 1):59-63.

二级参考文献8

1Kuchulakanti PK,Chu WW,Torguson R, et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus and paelitaxel eluting stents[J]. Circulation, 2006,113(8) : 1108-1113.
2Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel- eluting stents in routine clinical practice: data from a large two-institutional cohort study [J]. l.ancet, 2007, 369 ( 9562 ) : 667-678.
3Gurbel PA, Bliden KP, Samara W, et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study[J]. J Am Coil Cardiol,2005,46(10): 1827- 1832.
4Pinto Slottow TL, t3onello L, Gavani R, et al. Prevalence of aspirin and clopidogrel resistance among patients with and without drng-eluting stent thrombosis [J]. Am J Cardiol, 2009,104(4) :525-530.
5Gum PA, Kottke-Marchant K, Welsh PA, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease [J]. J Am Coll Cardiol,2003,41(6) : 961-965.
6Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate[J]. J Am Coil Cardiol, 2010,56(12) :919-933.
7Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents[J]. JAMA, 2005,293 (17) : 2126-2130.
8Rajendran S, Parikh D, Shuqman I, et al. High on treatment platelet reactivity and stent thrombosis[J]. Heart Lung Circ, 2011,20(8) : 525-531.